Chemoradiation With SABR Boost Safe, Effective for Advanced Lung Cancer
16 Jan 2024
Clinical Result
TUESDAY, Jan. 16, 2024 -- Chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost is safe and effective for patients with locally advanced, unresectable non–small cell lung cancer (NSCLC), according to a study published online Jan. 11 in JAMA Oncology.
Trudy C. Wu, M.D., from the University of California in Los Angeles, and colleagues examined the maximum tolerated dose (MTD) and use of hypofractionated concurrent chemoradiation with an adaptive SABR boost among patients with clinical stage II or III NSCLC. All patients first received 4 Gy x 10 fractions followed by an adaptive SABR boost consisting of an additional 25 Gy (low), 30 Gy (intermediate), or 35 Gy (high) with concurrent weekly carboplatin/paclitaxel. Data were evaluated from 28 patients (24 with stage III disease) enrolled across the low-, intermediate-, and high-dose cohorts (10, nine, and nine, respectively).
The researchers found that the protocol-specified MTD was not exceeded in the study. Nonhematologic acute and late grade 3 or higher effects had incidences of 11 and 7 percent, respectively. In the intermediate-dose boost cohort, there were no grade 3 toxic effects. In the high-dose cohort, there were two deaths. For the low-, intermediate-, and high-dose cohorts, two-year local control was 74.1, 85.7, and 100.0 percent, respectively, and two-year overall survival was 30.0, 76.2, and 55.6 percent, respectively.
"The present findings suggest that increasing the BED [biologic effective dose] through hypofractionation may enhance LC [local control], but this approach is limited by grade 5 toxic effects beyond a certain BED, which was 70 Gy in 15 fractions in this study," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.